ZELTIA NEWS: A selection of recent trials with trabectedin (Yondelis®), the marine-based drug developed by PharmaMar, the Grupo Zeltia (MC:ZEL) biotechnology subsidiary, was the central focus of the scientific programme at one of the leading international oncology events
The combination of trabectedin+doxorubicin offers significant clinical benefits in patients with metastatic uterine leiomyosarcoma and soft tissue leiomyosarcoma, with an acceptable safety profile
Trabectedin can be considered as an option for first-line treatment in translocation-related sarcomas.
...